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Abstract
Background: Mycobacterium tuberculosis (Mtb) infection may cause overt disease or remain latent. Interferon gamma release
assays (IGRAs) detect Mtb infection, both latent infection and infection manifesting as overt disease, by measuring whole-
blood interferon gamma (IFN-c) responses to Mtb antigens such as early secreted antigenic target-6 (ESAT-6), culture filtrate
protein 10 (CFP-10), and TB7.7. Due to a lack of adequate diagnostic standards for confirming latent Mtb infection, IGRA
sensitivity for detecting Mtb infection has been estimated using patients with culture-confirmed tuberculosis (CCTB) for
whom recovery of Mtb confirms the infection. In this study, cytokines in addition to IFN-c were assessed for potential to
provide robust measures of Mtb infection.
Methods: Cytokine responses to ESAT-6, CFP-10, TB7.7, or combinations of these Mtb antigens, for patients with CCTB were
compared with responses for subjects at low risk for Mtb infection (controls). Three different multiplexed immunoassays
were used to measure concentrations of 9 to 20 different cytokines. Responses were calculated by subtracting background
cytokine concentrations from cytokine concentrations in plasma from blood stimulated with Mtb antigens.
Results: Two assays demonstrated that ESAT-6, CFP-10, ESAT-6+CFP-10, and ESAT-6+CFP-10+TB7.7 stimulated the release of
significantly greater amounts of IFN-c, IL-2, IL-8, MCP-1 and MIP-1b for CCTB patients than for controls. Responses to
combination antigens were, or tended to be, greater than responses to individual antigens. A third assay, using whole blood
stimulation with ESAT-6+CFP-10+TB7.7, revealed significantly greater IFN-c, IL-2, IL-6, IL-8, IP-10, MCP-1, MIP-1b, and TNF-a
responses among patients compared with controls. One CCTB patient with a falsely negative IFN-c response had elevated
responses with other cytokines.
Conclusions: Multiple cytokines are released when whole blood from patients with CCTB is stimulated with Mtb antigens.
Measurement of multiple cytokine responses may improve diagnostic sensitivity for Mtb infection compared with
assessment of IFN-c alone.
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Tuberculosisremains a publichealth threatand is a leadingcause
of death worldwide, with an estimated 1.7 million deaths annually
[1]. Approximately one third of the world’s population are infected
with the causative bacterium, Mycobacterium tuberculosis (Mtb),a n da t
risk for developing tuberculosis disease. Without intervention,
approximately five to ten percent of those latently infected will
develop overt disease and the potentialto transmit Mtb to others [2].
Measurement of the IFN-c response to Mtb antigens has proven
useful in detecting Mtb infection, both latent infection and infection
manifesting as overt disease [3–5]. These assays, referred to as IFN-
c release assays (IGRAs), use enzyme-linked immunosorbent assays
(ELISAs) to measure differences in the concentration of IFN-c,o r
enzyme-linked immunospot assays (ELISpots) to measure differ-
ences in the number of cells that produce IFN-c, after incubation of
whole blood or peripheral blood mononuclear cells (PBMCs) with
Mtb antigens. Initially, IGRAs assessed response to tuberculin
purified protein derivative (PPD) or culture filtrate of Mtb [6,7].
Eventually, proteins that are present in Mtb but absent from bacillus
Calmette-Gue ´rin (BCG) vaccine strains and most nontuberculous
mycobacteria were found to improve IGRA specificity [8–12].
Early-secreted antigenic target-6 (ESAT-6), culture filtrate protein
10 (CFP-10), and TB7.7 (also called Rv2654) can induce IFN-c
release, and manufactured peptides representing these Mtb proteins
are used in various combinations as antigenic stimuli in commer-
cially available IGRAs designed to detect Mtb infection [4,13,14].
While estimates of IGRA specificity for Mtb infection are generally
high, estimates of IGRA sensitivity vary widely and in most
situations are less than ideal. Estimates of IGRA sensitivity range
from 70 to 90% based on pooled data from published reviews
involving predominantly adults with Mtb infection that was
confirmed by culture, i.e., adults with culture-confirmed tubercu-
losis (CCTB) [3,4]. Studies in high TB-endemic countries have
shown lower IGRA sensitivity than studies in low TB-endemic
countries [3]. Suboptimal IGRA sensitivity may result from a
reduction in IFN-c release in patients with active or advanced
tuberculosis and the fact that fewer antigenic epitopes are presented
by specific Mtb antigens compared with PPD. A lack of accurate
diagnostic standards hampers attempts to estimate test sensitivity for
latent Mtb infection. There is no gold diagnostic standard with
which to confirm the presence of latent Mtb infection. However,
recovery of Mtb by culture in a patient with symptoms compatible
with tuberculosis is adequate confirmation for Mtb infection, and
has been used in most studies to estimate IGRA sensitivity [3,4].
Other cytokines used in combination or as alternatives to IFN-c
may improve sensitivity for detecting Mtb infection. Use of antigens
in combination (e.g., ESAT-6, CFP-10, & TB7.7 combined) may
also increase analytic and clinical sensitivity by increasing the
number of epitopes available to stimulate lymphocytes, thus
increasing the amount of cytokine released.
Numerous cytokines have been implicated in the pathogenesis
and control of Mtb infection [15–26]. Measurement of multiple
proinflammatory and anti-inflammatory cytokines, chemokines,
and growth factors associated with Mtb infection (collectively
referred to as cytokines for simplicity) may facilitate its detection.
T h eo b j e c t i v e so ft h i ss t u d yw e r e :1 )t oa s s e s st h er e s p o n s e so f
multiple cytokines to individual and combinations of Mtb antigens, 2)
to compare the diagnostic potential of other cytokines with IFN-c for
detecting Mtb infection, and 3) to determine if measurement of
multiple cytokines can improve detection accuracy. To increase the
likelihood of identifying diagnostically important alternative cytokines,
we studied subjects categorized with a high degree of confidence into
those with Mtb infection (i.e., patients with CCTB) and those without
infection (low-risk control subjects), and used three different
multiplexed assays that examined different panels of cytokines.
Materials and Methods
Ethics Statement and Plasma Selection
We previously described comparisons of tuberculin skin test
(TST) and QuantiFERONH-TB Gold test (QFT-G, Cellestis Ltd.,
Victoria, Australia) results among patients with suspected tubercu-
losis [27] and among low-risk Navy recruits [28]. People were
excluded if they were known to have received .7 days of therapy
for tuberculosis or latent Mtb infection. During these studies, most
subjects provided blood for evaluation of additional cytokines and
antigens after providing written informed consent as approved by
Human Subjects Protection Review Boards at all participating
institutions: the Centers for Disease Control and Prevention (CDC)
Institutional Review Board (IRB), the Boston University Medical
Center IRB, the Colorado Multiple Institutional Review Board for
Denver Public Health Department, the University of North Texas
Health Science Center at Fort Worth and Texas College of
Osteopathic Medicine IRB for the Protection of Human Subjects,
theNationalNavalMedical CenterIRB,theUniversityofMedicine
and Dentistry of New Jersey IRB, the San Diego State University
IRB, and the University of California, San Francisco Committee on
Human Research. Subjects consented to provide at least 5 mL of
blood for the parent study, but could provide up to 30 mL of blood
(to allow evaluation of other tests) if possible without additional
venipuncture. When the volume of blood was adequate, one-mL
aliquots of heparinized blood were incubated simultaneously with
saline (Nil), phytohemagglutinin A (mitogen), and cocktails of
overlapping peptides representing Mtb antigens, including ESAT-6,
CFP-10, TB7.7, and combinations of these antigens (ESAT-
6+CFP-10 or ESAT-6+CFP-10+TB7.7), for 16 to 24 hours at
37uC within 12 hours of collection. The peptides simulating ESAT-
6 and CFP-10 were identical to those used in QFT-G and the
QuantiFERON-TB Gold In-Tube test (QFT-GIT); the peptide
representing TB7.7 was identical to that used in QFT-GIT; the
peptide cocktails were provided by Cellestis Ltd., Victoria,
Australia. After incubation, the plasma supernatants were trans-
ferred to micro-tubes in 96-well format, and frozen at 280uC.
Stored plasma samples from a convenient number of patients
(N=21) with CCTB and from a similar number of subjects
(N=24) at low risk for Mtb infection (controls) were selected (as
depicted in Figures 1A–B) for evaluation. Funding limitations
determined the number of samples assayed. Stored plasma
samples from subjects with HIV infection or indeterminate
QFT-G results were not included; otherwise, plasma was selected
by convenience sampling from lists of patients with CCTB and
subjects at low risk of Mtb infection without other bias. Clinical
and epidemiologic data were collected as part of the parent study.
Patients with symptoms or signs of active tuberculosis were
considered to have CCTB if Mtb was recovered from one or more
clinical specimens by culture. Subjects were eligible to be controls
and presumed to be uninfected if they denied contact with persons
with tuberculosis, were not born (or had not lived .1 month) in a
country with an estimated TB prevalence higher than 20 per
100,000 population based on reported nativity and estimates of
TB prevalence for 1990 [29], and had not resided, worked or
volunteered .1 month at a homeless shelter, prison, drug
rehabilitation unit, hospital, or nursing home.
For this study, stored plasma was thawed, aliquoted, and
assayed immediately or aliquots were refrozen and thawed once
for additional assays. When possible, plasma from the same subject
was tested with more than one multiplexed immunoassay.
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available plasma and in the allowed number of freeze-thaw cycles.
Measurement of IFN-c by ELISA
IFN-c concentrations were measured by a commercial ELISA
using methods and reagents as previously described for the QFT-
G [27]. The concentrations of IFN-c reported in international
units/mL (IU/mL) were converted to pg/mL by multiplying by
40 pg/IU [30]. When the optical density for a plasma sample was
higher than that of the highest standard, which was common
following mitogen stimulation, the value was extrapolated.
Measurement of Cytokine Concentrations by In-house
MMIA
An in-house multiplexed microsphere-based immunoassay
(MMIA), also called suspension array, was modified to measure
the concentrations of 10 different cytokines. An 8-plex assay that
was developed and validated using Luminex technology (Luminex
Corp., Austin, TX) for IFN-c, TNF-a, IL-2, IL-4, IL-6, IL-8, IL-
10 and IL-12 (p70) [31], was modified to include VEGF
(BioSource/Invitrogen, Carlsbad, CA) and IL-1b (R&D Systems,
Minneapolis, MN). The resulting 10-plex cytokine immunoassay
was validated by testing for both cross-reactivity of reagents and
recovery of spiked multiplexed cytokine standards, as described
previously [32,33]. The assay proceeded as described previously
[31]. Briefly, the multiplexed immunoassay was performed by
combining all 10 cytokine standards at a concentration of
5000 pg/mL each in phosphate-buffered saline, pH 7.4–0.5%
bovine serum albumin 20.02% sodium azide (PBN) and serially
diluting the mixture three-fold to obtain concentrations in the
range of 5000 to 2.29 pg/mL for the standard curves. Pooled
normal human plasma (pretested to ensure undetectable cytokine
levels) was added so that the volume of plasma in the standards
was equal to the final volume of plasma in each sample. Subject
samples were diluted 1:5 in PBN. The assay proceeded with the
Figure 1. (A–B): Study participation diagram. Panel A depicts selection of 21 patients with culture-confirmed tuberculosis (patients) from
among 179 tuberculosis (TB) suspects enrolled in a previously described study [27]. Panel B depicts selection of 24 subjects at low risk for Mtb
infection (controls) from among 866 Navy recruits enrolled in a previously described study [28]. No significant differences in characteristics of those
selected or not selected were observed. Plasma samples from all 21 patients and 24 controls were assessed by the commercial ELISA,
QuantiFERON-TB Gold test (QFT-G). Plasma samples from 6 patients and 10 controls were assessed by the in-house MMIA. Plasma samples from 6
patients and 7 controls were assessed by the microarray. Plasma samples from 12 patients and 12 control subjects were assessed by the
commercial MMIA.
doi:10.1371/journal.pone.0026545.g001
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microspheres (Luminex Corp., Austin, TX), each coupled with a
capture antibody for one of the 10 analytes, similarly mixed
biotinylated detection antibodies, and finally the reporter,
streptavidin phycoerythrin, in a series of incubation steps and
washes similar to ELISA methodology. A minimum of one
hundred microspheres per cytokine was acquired on a compact
flow cytometer (Luminex 100) and the median fluorescent
intensity (MFI) of the phycoerythrin conjugate for each micro-
sphere set in each well was reported. Blank values (from wells with
all reagents except cytokine or sample) were subtracted from all
readings and the concentrations of unknowns were calculated from
the standard curves derived with a weighted 5-parameter logistic
(5PL) curve-fitting model (Bio-Plex Manager 3.0 and 4.1.1).
Values that fell below the lowest range for the standard curve were
recorded as 0 pg/mL and upper values were set at 25,000 pg/mL.
The precision of the in-house 10-plex assays for this study
averaged 7.8% (intra-assay variability, range 5–12% for all
cytokines, n=10). The average lowest range for each cytokine
standard was: IL-2 (2.4 pg/mL), IL-4 (2.5 pg/mL), IL-6 (2.7 pg/
mL), IL-8 (2.3 pg/mL), IL-10 (2.2 pg/mL), IL-12 (2.4 pg/mL),
TNF-a (2.3 pg/mL), IFN-c (1.9 pg/mL), IL-1b (2.3 pg/mL) and
VEGF (7.3 pg/mL) (n=10, except for VEGF, n=8; average
CV=0.43).
Measurement of Cytokine Concentrations by Microarray
A commercial quantitative immuno-microarray (Microarray,
Quantibody Human Cytokine Array 1, RayBiotech, Inc.,
Norcross, GA) was used to measure the concentrations of 20
cytokines in plasma samples; specifically, IFN-c, IL-1a, IL-1b, IL-
2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12, IL-13, GM-CSF, GRO,
MCP-1, MIP-1a, MIP-1b, MMP-9, RANTES, TNF-a, and
VEGF were measured. The manufacturer’s procedure was
followed and the results were analyzed with the RayBiotech Q
Analyzer program. Samples and standards were diluted in the
Sample Diluent provided with each kit. The standard curves for
each cytokine varied in range from a low of 5–400 pg/mL for IL-
13 to 370–30,000 pg/mL for MMP-9. The procedure was similar
to that used for the in-house MMIA and ELISA, with the
detection antibodies labeled with Alexa 555 that was measured
with an Axon Gene Pix 4200 A laser scanner (Molecular Devices,
Silicon Valley, CA) at a wavelength of 555 and settings of 450, 550
and 650 pmt. Standard curves were analyzed by regression based
on linear and logarithmic transformations of the data. The results
of any one assay were based on the same pmt readings and data
transformation for all cytokines if the correlation coefficient was
$0.90 for the standard curve. Data not meeting this latter
criterion were excluded.
Measurement of Cytokine Concentrations by a Custom
Commercial MMIA
A custom commercial MMIA (Bio-Plex Cytokine Assay, Bio-
Rad Laboratories, Hercules, CA) was used to measure 9 cytokines:
IFN-c, IL-2, IL-6, IL-8, IL-12, IP-10, MCP-1, MIP-1b, and TNF-
a. This assay was used to examine responses to the combination
antigen, ESAT-6+CFP-10+TB7.7, and included samples from
additional patients with CCTB and controls. The manufacturer’s
instructions for performing and interpreting the assay were
followed and were similar to those used for the in-house MMIA.
Samples and standards were diluted with Human Serum Sample
Diluent and Human Serum Standard Diluent, respectively. The
ranges of the standard curves varied for each cytokine. When
cytokine concentrations were higher than the upper range of the
standard curves (i.e. for MCP-1 and MIP-1b), the values were
reported as the upper range multiplied by the dilution factor.
Statistical Analysis
Statistical analyses were conducted with SPSS statistical software
(Ver. 15.0, SPSS Inc., Chicago, Ill). The Mann-Whitney U test (also
known as the Wilcoxon rank-sum test) was used to compare age of
patients with CCTB versus low-risk control subjects. The Chi-
squaredtestor,whenanexpected frequencywasfive orless,Fisher’s
Exact test was used to compare proportions for other subject
characteristics. Each cytokine response was determined by
subtracting the background cytokine concentration in plasma from
blood incubated with saline (Nil) from the cytokine concentration in
plasma from blood stimulated with mitogen or Mtb antigens.
Sensitivity was calculated by dividing the number of patients with
CCTB and positive results by the number tested; specificity was
calculated by dividing the number of low-risk control subjects with
negative results by the number of controls tested. The Mann-
Whitney U test was used to compare background cytokine
concentrations (and cytokine responses) of patients with CCTB
with the background concentrations (or responses) of control
subjects. The Wilcoxon signed-rank test was used to compare
cytokine responsesto different antigens amongpatients with CCTB.
P values ,0.05 were considered significant. Dot-plots were
prepared with Analyse-it for Microsoft Excel v2.20 (Analyse-it
Software, Ltd., Leeds, United Kingdom). Histograms were
prepared by Microsoft Office Excel 2007.
Results
Characteristics of the 21 patients with CCTB and the 24 low-risk
control subjects selected for this study are summarized in Table 1.
Significant differences in age, sex, ethnicity, prevalence of
tuberculosis in the country of birth, and BCG vaccination status
existedbetweenthetwopopulations.TSTindurationrangedfrom0
to 33 mm (mean=18, median=19) among CCTB patients, and
was0 forallcontrolsubjects. Because of limitations intheamount of
available plasma and in the number of allowed freeze-thaw cycles,
none of the plasma specimens were tested in all three multiplexed
immunoassays; five patient and 5 control plasmas were analyzed in
two different multiplexed assays. These limitations and failure of
portions of an assay to meet quality control criteria occasionally
caused data to be missing for an antigen or cytokine for a few
samples. Characteristics of the 21 CCTB patients tested by the
commercial ELISA did not differ significantly from characteristics
of the 6 patients tested by in-house MMIA, the 6 patients tested by
microarray, or the 12 patients tested by commercial MMIA.
Plasmas from a similar number of CCTB patients and control
subjects were tested with each assay.
As shown in Table 2 for measurements by commercial ELISA,
highly significant differences in IFN-c responses to ESAT-6, CFP-
10, TB7.7, ESAT-6+CFP-10, and ESAT-6+CFP-10+TB7.7 were
observed for CCTB patients compared with controls (p for each
comparison ,0.001). While the difference in the median IFN-c
response to TB7.7 for patients compared with controls was small
(3 vs. 0 pg/mL), the difference was statistically significant
(p,0.001). As shown in Table 3 for CCTB patients, the difference
in IFN-c response to ESAT-6+CFP-10 versus ESAT-6+CFP-
10+TB7.7 was not significant (p=0.327), but responses to the
combination antigens were significantly greater than the responses
to the individual antigens (p ranged from #0.001 to 0.007). When
a cutoff of 14 pg/mL (equivalent to the 0.35 IU/ml cutoff
approved by the FDA for the QFT-G and QuantiFERON-TB
Gold In-Tube test) was used to separate positive and negative
Cytokine Responses to M. tuberculosis Antigens
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CCTB patients were classified as positive and 23 (100%) of 23
controls were classified as negative (one patient and one control
did not have ELISA results for plasma stimulated with ESAT-
6+CFP-10+TB7.7). None of the Mtb antigens, including ESAT-
6+CFP-10+TB7.7, induced a measureable IFN-c response for one
patient with CCTB.
Cytokine responses measured by in-house MMIA are shown in
Table 4. Comparisons of responses to ESAT-6 show significantly
greater responses for CCTB patients compared with controls for
IFN-c (94 vs. 0 pg/mL, p=0.006), IL-2 (116 vs. 0 pg/mL,
p,0.001), and IL-8 (207 vs. 23 pg/mL, p=0.003). Similarly,
significant differences in these cytokine responses, as well as IL-6
responses, were found following stimulation with CFP-10, ESAT-
6+CFP-10, and ESAT-6+CFP-10+TB7.7. In contrast to findings
with ELISA, no difference in IFN-c response to TB7.7 was
observed between patients and controls with the in-house MMIA
(p=0.094), which had a much smaller sample size (N=16 vs.
N=45). Similarly, no differences in responses to TB7.7 were
observed between patients and controls with other cytokines
included in the in-house MMIA. IL-1b, IL-4, IL-10, and TNF-a
responses to antigen stimulation were generally very low. Several
control subjects had detectable IL-12 responses but responses to
mitogen were low. The background values for VEGF were higher
for CCTB patients compared with controls. As shown in Table 5,
responses for CCTB patients to combination antigens tended to be
greater (lower p values) than for individual antigens for IFN-c, IL-
2, IL-6, and IL-8.
As shown in Tables 6 and 7, microarray analysis for 20
cytokines confirmed that IFN-c, IL-2, IL-8, and variably IL-6
responses to Mtb antigens were significantly greater for patients
with CCTB than for controls. In addition, MCP-1 and MIP-1b
responses to the Mtb antigens tested were significantly higher for
patients than controls, and MIP-1a responses were significantly
greater for the antigen combinations. No consistent trend in
differences between individual and combinations of Mtb antigens
was evident for patients with this method (Table 8).
Additional samples were analyzed to confirm findings from the
previous two assays. For this analysis a custom commercial MMIA
was chosen and a chemokine not yet tested, IP-10, was included.
As shown in Table 9, IFN-c, IL-2, IL-6, IL-8, IP-10, MCP-1,
MIP-1b and TNF-a responses were significantly greater for CCTB
patients compared with controls after whole blood was stimulated
with ESAT-6+CFP-10+TB7.7. In addition, background IP-10,
MCP-1, and MIP-1b concentrations in plasma from unstimulated
blood (Nil) from patients were significantly greater than from
controls. IL-12 responses were low and not significant. Another
observation was that the IL-2 Mitogen response was significantly
Table 1. Demographic and clinical characteristics of participants.
Patients Controls p-value
Number of subjects participating in analysis 21 24
Mean age in years 43 20
Median age 45 20 ,0.001
Minimum age 21 17
Maximum age 80 25
Sex: Male 8 (38.1) 23 (95.8) ,0.001
Race/Ethnicity - Number (percentage)
White non-Hispanic 1 (4.8) 16 (66.7) ,0.001
Black non-Hispanic 5 (23.8) 5 (20.8)
Asian, Pacific Islander, or Native American 5 (23.8) 1 (4.2)
Hispanic 10(47.6) 2 (8.3)
Born in a country with indicated TB burden - Number (percentage)
,20 cases per 100,000 population 8 (38.1) 24 (100) ,0.001
20 to 100 cases per 100,000 population 5 (23.8) 0 (0)
.100 cases per 100,000 population 8 (38.1) 0 (0)
Resided in a country with indicated TB burden (other than birth) - Number (Percentage)
,20 cases per 100,000 population 18 (85.7) 24 (100) ,0.16
20 to 100 cases per 100,000 population 2 (9.5) 0 (0)
.100 cases per 100,000 population 1 (4.8) 0 (0)
Employed or stayed in a health care facility for .1 month- Number (Percentage) 4 (19.0) 0 (0) 0.04
Employed or stayed in a correctional facility for .1 month- Number (Percentage) 5 (23.8) 0 (0) 0.02
History of BCG vaccination- Number (Percentage)
None 9 (42.9) 24 (100) ,0.001
Unknown 3( 9 . 5 ) 0( 0 )
Vaccinated 10 (47.6) 0 (0)
Characteristics are listed for 21 patients with culture-confirmed tuberculosis (patients) and 24 subjects at low-risk for M. tuberculosis (Mtb)exposure (controls) who
provided samples that were tested in this study. Samples from 5 patients and 6 controls were tested with more than one multiplexed immunoassay. Percentages of the
patients or controls in the different categories are indicated in parentheses. The Mann-Whitney U test was used to compare age. Other p values were calculated by the
Chi-squared test or, when an expected frequency was five or less, a Fisher’s Exact test.
doi:10.1371/journal.pone.0026545.t001
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the results shown in Table 4, but was not significant.
Dot-plots (Figures 2A–H) and histograms (Figures 3A–B)
showing patterns of cytokine responses represented in Table 9,
illustrate the dramatic cytokine activity that occurs when whole
blood from CCTB patients are stimulated with ESAT-6+CFP-
10+TB7.7. The split y-axis at 2000 pg/mL highlights the
tremendous IP-10, MCP-1, and MIP-1b responses seen for the
majority of patients. Sensitivity and specificity were 100% with IL-
2, IL-6, IP-10, and MIP-1b, based on cutoffs equal to the mean
responses to ESAT-6+CFP-10+TB7.7 plus three standard devia-
tions for control subjects. With IFN-c measured by the custom
commercial MMIA, similar calculations demonstrated a specificity
of 100% with a sensitivity of 91.6%. One CCTB patient classified
as negative based on the IFN-c response was considered positive
based on the responses of IL-2, IL-6, IL-8, IP-10, or MIP-1b. This
subject was also classified as negative based on the IFN-c response
to ESAT-6+CFP-10+TB7.7 as well as other Mtb antigens
measured by commercial ELISA.
Discussion
The sensitivity of FDA approved IGRAs is less than ideal, and
typically no better than the sensitivity of the TST [3,4]. This pilot
study was designed to investigate the use of other cytokines as
markers of Mtb infection and to evaluate the potential impact of
their use on detection sensitivity. Cytokine responses to individual
Mtb antigens and antigen combinations were compared.
Each of three multiplexed assays demonstrated that in addition
to IFN-c, multiple cytokines are released in response to Mtb
antigens with significantly greater responses among patients with
CCTB than among control subjects. The in-house MMIA and
microarray demonstrated that IFN-c, IL-2, IL-6, and IL-8
responses to the combination antigen ESAT-6+CFP-10+TB7.7
were greater among patients than among controls. In addition, the
microarray data demonstrated significantly greater MCP-1, MIP-
1a, and MIP -1b responses among patients. The custom
commercial MMIA confirmed that multiple cytokines were
released in response to Mtb antigens, and that IFN-c, IL-2, IL-6,
IL-8, IP-10, MCP-1, MIP-1b, and TNF-a responses to ESAT-
6+CFP-10+TB7.7 were significantly greater for patients than for
controls. Four of these cytokines appear to be excellent candidates
as diagnostic markers of Mtb infection; sensitivity and specificity
were 100% with IL-2, IL-6, IP-10, and MIP-1b. In contrast, IFN-
c sensitivity with the custom commercial MMIA was 91.6% and
specificity was 100%.
O n eC C T Bp a t i e n tf a i l e dt od e m o n s t r a t ea nI F N - c response
with any of the Mtb antigens using multiple test formats
Table 2. Cytokine concentrations and responses measured with a commercial ELISA.
Cytokine
Subject
Group Nil
Mitogen
Response
ESAT-6
Response
CFP-10
Response
TB7.7
Response
ESAT-6+CFP-10
Response
ESAT-6+CFP-
10+TB7.7
Response
IFN-c Patients 8 524 61 128 3 187* 202*
(2 to 18) (28 to 1,035) (10 to 756) (0 to 676) (22 to 124) (21 to 757) (22t o7 5 7 )
C o n t r o l s 4 6 6 5 0000 0 * *
(3 to 15) (103 to 2,040) (27t o9 ) ( 28t o8 ) ( 28t o4 ) ( 24t o1 ) ( 27t o1 )
p-value 0.062 0.158 ,0.001 ,0.001 ,0.001 ,0.001 ,0.001
Median background IFN-c concentrations (Nil, pg/mL) and IFN-c responses (pg/mL) to phytohemagglutinin (Mitogen Response), early secreted antigenic target-6 (ESAT-
6 Response), culture filtrate protein 10 (CFP-10 Response), TB7.7 (TB7.7 Response), and combinations of these M. tuberculosis (Mtb) antigens (ESAT-6+CFP-10 Response,
and ESAT-6+CFP-10+TB7.7 Response) are listed with ranges in parentheses. Cytokine concentrations were measured with a commercial enzyme-linked immunosorbent
assay (ELISA) for patients with culture-confirmed tuberculosis (patients) and subjects at low-risk of Mtb exposure (controls). Responses were calculated by subtracting
the background cytokine concentration in plasma from blood incubated with saline (Nil) from the cytokine concentration in plasma from blood incubated with mitogen
or Mtb antigens. N=21 for patients and N=24 for controls unless indicated (*n=20, **n=23). P values were calculated by Mann-Whitney U Rank Sum test comparing
cytokine concentrations or responses for patients with controls. Significant differences (p,0.05) are indicated in bold type.
doi:10.1371/journal.pone.0026545.t002
Table 3. Comparisons of IFN-c responses to different antigens measured by commercial ELISA among patients with culture-
confirmed tuberculosis.
Cytokine ESAT-6 ESAT-6 ESAT-6 ESAT-6 CFP-10 CFP-10 CFP-10 TB7.7 TB7.7
ESAT-6+CFP-
10
vs. vs. vs. vs. vs. vs. vs. vs. vs. vs.
CFP-10 TB7.7 ESAT-6+
CFP-10
ESAT-6+CFP-
10+TB7.7
TB7.7 ESAT-6+
CFP-10
ESAT-6+CFP-
10+TB7.7
ESAT-6+
CFP-10
ESAT-6+CFP-
10+TB7.7
ESAT-6+CFP-
10+TB7.7
IFN-c 61 61 61 61 128 128 128 3 3 187
vs. vs. vs. vs. vs. vs. vs. vs. vs. vs.
128 3 187 202 3 187 202 187 202 202
(0.794) (,0.001) (0.007) (0.006) (,0.001) (0.005) (0.005) (,0.001) (,0.001) (0.327)
Median IFN-c responses (from Table 2) to early secreted antigenic target-6 (ESAT-6), culture filtrate protein 10 (CFP-10), TB7.7, and combinations of these antigens for
patients with culture-confirmed tuberculosis (patients) are listed with p values in parenthesis calculated by Mann-Whitney U Rank Sum test. Significant differences
(p,0.05) are indicated in bold type.
doi:10.1371/journal.pone.0026545.t003
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Cytokine Subject GroupNil
Mitogen
Response
ESAT-6
Response
CFP-10
Response
TB7.7
Response
ESAT-6+CFP-
10 Response
ESAT-6+CFP-
10+TB7.7
Response
IFN-c Patients 0 4,651 94 349 0 366 380
(0 to 101) (229 to 8,890) (0 to 629) (109 to 902) (24 to 58) (132 to 590) (255 to 1,570)
Controls 8 3,743 0 0 0 0 0
(0 to 62) (986 to 21,395) (241 to 12) (28t o2 3 ) ( 231 to 0) (223 to 39) (222 to 10)
p-value 0.550 0.828 0.006 0.001 0.094 0.001 0.001
IL-1b Patients 0 19 0 0 0 0 0
(0 to 16) (211 to 53) (0 to 1) (0 to 3) (24t o0 ) ( 23t o0 ) ( 22t o1 6 7 )
Controls 0 7 0 0 0 0 0
( 0t o0 ) ( 0t o7 3 ) ( 0t o0 ) ( 0t o0 ) ( 0t o0 ) ( 0t o0 ) ( 0t o0 )
p-value 0.197 0.821 0.197 0.197 0.197 0.197 0.426
IL-2 Patients 0 281 116 216 0 238 300
(0 to 14) (0 to 1,134) (0 to 293) (0 to 424) (0 to 1) (0 to 532) (0 to 711)
Controls 0 543 0 0 0 0 0
(0 to 0) (210 to 1,156) (0 to 0) (0 to 0) (0 to 0) (0 to 12) (0 to 16)
p-value 0.197 0.329 0.001 0.001 0.197 0.002 0.006
IL-4 Patients 0 51 0 0 0 0 0
(0 to 17) (0 to 78) (217 to 13) (217 to 0) (217 to 16) (217 to 0) (217 to 0)
Controls 12 55 0 0 0 0 0
(0 to 41) (23t o1 9 8 ) ( 26 to 11) (0 to 38) (214 to 27) (241 to 18) (29t o1 0 3 )
p-value 0.120 0.625 0.663 0.048 0.487 0.152 0.232
IL-6 Patients 11 3,828 15 20 0 20 151
(0 to 60) (372 to 23,840) (0 to 28) (10 to 55) (221 to 9) (12 to 14,558) (7 to 22,167)
Controls 0 3,467 0 0 0 1 0
(0 to 12) (2,329 to 13,567) (212 to 22) (212 to 18) (212 to 0) (0 to 24) (212 to 29)
p-value 0.114 1.000 0.066 0.002 1.000 0.015 0.005
IL-8 Patients 91
4,539
207 1,227 94
1,051
2,274
(0 to 157) (412 to 7,790) (117 to 1,842) (187 to 3,086) (22 to 213) (644 to 24,871) (336 to 24,814)
Controls 105 2,151 23 14 37 21 40
(15 to 290) (939 to 13,360) (2106 to 187) (240 to 43) (243 to 193) (230 to 208) (244 to 193)
p-value 0.625 1.000 0.003 0.001 0.278 0.001 0.001
IL-10 Patients 0 105 0 0 0 0 0
(0 to 24) (0 to 653) (0 to 1) (25t o0 ) ( 28t o0 ) ( 24 to 50) (0 to 20)
Controls 0 206 0 0 0 0 0
(0 to 0) (60 to 404) (0 to 13) (0 to 0) (0 to 0) (0 to 0) (0 to 0)
p-value 0.197 0.448 0.750 0.197 0.197 1.000 0.059
IL-12 Patients 0 0 0 0 0 0 0
(0 to 20) (221 to 0) (0 to 4) (23t o0 ) ( 23t o0 ) ( 23t o0 ) ( 24t o0 )
Controls 10 216 1 0 0 1 1
(0 to 24) (248 to 11) (28 to 34) (0 to 26) (218 to 22) (23 to 19) (210 to 23)
p-value 0.169 0.245 0.339 0.112 0.720 0.083 0.223
TNF-a Patients 0 159 0 0 0 0 1
(0 to 23) (0 to 828) (0 to 6) (0 to 0) (25t o0 ) ( 21t o0 ) ( 0t o9 1 )
Controls 0 49 0 0 0 0 0
( 0t o0 ) ( 2 1t o3 6 5 ) ( 0t o0 ) ( 0t o0 ) ( 0t o0 ) ( 0t o0 ) ( 0t o0 )
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mitogen, no other evidence of immune dysfunction, nor any
unusual IFN-c measurements to suggest laboratory errors. In
stark contrast to the lack of IFN-c response, this subject’s IL-2,
IL-6, IL-8, IP-10, and MIP-1b responses to ESAT-6+CFP-
10+TB7.7 were greater than corresponding mean responses
plus three standard deviations for controls. This observation
demonstrates that the use of other cytokines in addition to
IFN-c or as alternatives to IFN-c can improve sensitivity for
detecting Mtb infection.
Plausible reasons for false-negative IGRA results include: 1)
measurement errors [34], 2) host-mediated inhibition of IFN-c
release [35], 3) drug or disease induced immune suppression
[36,37], 4) genetic defects in IFN-c production [38,39], and 5)
Major Histocompatibility Complex (MHC) determined restriction
in the ability to recognize presented epitopes [40]. The potential
Cytokine Subject GroupNil
Mitogen
Response
ESAT-6
Response
CFP-10
Response
TB7.7
Response
ESAT-6+CFP-
10 Response
ESAT-6+CFP-
10+TB7.7
Response
p-value 0.197 0.329 0.197 1.000 0.197 0.197 0.017
VEGF Patients 737 21,075 118 258 133 2104 2153
(358 to 954) (21,538 to 2525) (2128 to 842) (2242 to 665) (2178 to 546) (2291 to 411) (2680 to 0)
Controls 144* 2109* 87* 161* 229* 96* 74*
(0 to 758) (21,415 to 0) (2258 to 279) (2119 to 208) (2144 to 519) (2162 to 519) (2407 to 443)
p-value 0.037 0.109 0.631 0.522 0.631 0.109 0.173
Median background cytokine concentrations (Nil, pg/mL) and cytokine responses (pg/mL) to phytohemagglutinin (Mitogen Response), early secreted antigenic target-6
(ESAT-6 Response), culture filtrate protein 10 (CFP-10 Response), TB7.7 (TB7.7 Response), and combinations of these M. tuberculosis (Mtb) antigens (ESAT-6+CFP-10
Response and ESAT-6+CFP-10+TB7.7 Response) are listed with ranges in parentheses. Cytokine concentrations were measured with an in-house multiplexed
microsphere-based immunoassay (in-house MMIA) for patients with culture-confirmed tuberculosis (patients) and subjects at low-risk of Mtb exposure (controls). For
concentrations that were designated ‘‘out of range’’ by Bio-Plex Manager software, low values are reported as 0 and high values are reported as the upper limit of the
standard curve multiplied by the dilution factor (25,000 pg/mL). Responses were calculated by subtracting the background cytokine concentration in plasma from
blood incubated with saline (Nil) from the cytokine concentration in plasma from blood incubated with mitogen or Mtb antigens. N=6 for patients and N=10 for
controls unless indicated (*n=6). P values were calculated by Mann-Whitney U Rank Sum test comparing cytokine concentrations or responses for patients with
controls. Significant differences (p,0.05) are indicated in bold type.
doi:10.1371/journal.pone.0026545.t004
Table 4. Cont.
Table 5. Comparisons of cytokine responses to different antigens measured by in-house MMIA among patients with culture-
confirmed tuberculosis.
Cytokine ESAT-6 ESAT-6 ESAT-6 ESAT-6 CFP-10 CFP-10 CFP-10 TB7.7 TB7.7 ESAT-6+CFP-10
vs. vs. vs. vs. vs. vs. vs. vs. vs. vs.
CFP-10 TB7.7 ESAT-6+
CFP-10
ESAT-6+CFP-
10+TB7.7
TB7.7 ESAT-6+
CFP-10
ESAT-6+CFP-
10+TB7.7
ESAT-6+
CFP-10
ESAT-6+CFP-
10+TB7.7
ESAT-6+CFP-
10+TB7.7
IFN-c 94 94 94 94 349 349 349 0 0 366
vs. vs vs vs vs vs vs vs vs vs
349 0 366 380 0 366 380 366 380 380
(0.028) (0.043) (0.075) (0.028) (0.028) (0.463) (0.116) (0.028) (0.028) (0.345)
IL-2 116 116 116 116 216 216 216 0 0 0238
vs. vs vs vs vs vs vs vs vs vs
261 0 238 300 0 238 300 238 300 300
(0.043) (0.043) (0.138) (0.043) (0.043) (0.500) (0.080) (0.043) (0.043) (0.500)
IL-6 15 15 15 15 20 20 20 0 0 20
vs. vs vs vs vs vs vs vs vs vs
20 0 20 151 0 20 151 20 151 151
(0.058) (0.075) (0.074) (0.116) (0.028) (0.917) (0.173) (0.028) (0.028) (0.753)
IL-8 207 207 207 207 1,227 1,227 1,227 94 94 1,051
vs. vs vs vs vs vs vs vs vs vs
1,227 94 1,051 2,274 94 1,051 2,274 1,051 2,274 2,274
(0.028) (0.046) (0.249) (0.028) (0.028) (0.917) (0.463) (0.028) (0.028) (0.753)
Median cytokine responses (from Table 4) to early secreted antigenic target-6 (ESAT-6), culture filtrate protein 10 (CFP-10), TB7.7, and combinations of these M.
tuberculosis (Mtb) antigens for patients with culture-confirmed tuberculosis (patients) are listed with p values in parenthesis calculated by Mann-Whitney U Rank Sum
test. Significant differences (p,0.05) are indicated in bold type.
doi:10.1371/journal.pone.0026545.t005
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Cytokine Subject Group Nil ESAT-6 Response CFP-10 Response
ESAT-6+CFP-10
Response
ESAT-6+CFP-
10+TB7.7
Response
IFN-c Patients 37 682 763 1,270 1,259
(0 to 1,679) (87 to 3,600) (29 to 1,960) (42 to 5,808) (2639 to 7,977)
Controls 286 11 6 8 2
(8 to 74,712) (24,026 to 720) (24,738 to 831) (215,218 to 642) (214,924 to 22)
p-value 0.199 0.022 0.015 0.010 0.025
IL-1a Patients 40004 7
(1 to 413) (2162 to 14) (2411 to 56) (2411 to 207) (2411 to 95)
Controls 374 0 0 24 71
(1 to 2,859) (2277 to 666) (2184 to 2,251) (2358 to 2,107) (2511 to 306)
p-value 0.152 0.883 0.883 0.775 0.423
IL-1b Patients 30003 0
(1 to 133) (214 to 32) (248 to 27) (285 to 53) (2115 to 106)
Controls 17 0 0 29 25
(0 to 1,101) (2159 to 218) (2125 to 333) (2345 to 33) (2409 to 27)
p-value 0.520 0.319 0.868 0.289 0.173
IL-2 Patients 0 428 499 740 746
(0 to 92) (23 to 3,248) (39 to 2,251) (53 to 5,068) (64 to 6,820)
C o n t r o l s 72040
(0 to 423) (214 to 66) (226 to 74) (2112 to 87) (2170 to 11)
p-value 0.283 0.007 0.004 0.004 0.004
IL-4 Patients 30000
(0 to 374) (2120 to 62) (2120 to 0) (2207 to 378) (2120 to 19)
Controls 131 0 0 47 35
(0 to 3,291) (2136 to 51) (2110 to 434) (2591 to 433) (21,400 to 291)
p-value 0.430 0.557 0.351 0.304 0.245
IL-5 Patients 10000
(0 to 172) (253 to 27) (2115 to 6) (2133 to 15) (2168 to 53)
C o n t r o l s 60800
(0 to 783) (218 to 126) (0 to 166) (2167 to 146) (2252 to 24)
p-value 0.519 0.756 0.062 0.769 0.442
IL-6 Patients 7 250 28 182 781
(0 to 239) (2 to 874) (236 to 378) (235 to 1,639) (229 to 14,727)
C o n t r o l s 3 2 1028
(1 to 1,914) (2331 to 21) (280 to 151) (2413 to 143) (2706 to 26)
p-value 0.174 0.010 0.116 0.153 0.025
IL-8 Patients 124* 1,038* 1,988* 1,595* 3,076*
(27 to 595) (132 to 4,912) (469 to 4,913) (933 to 4,913) (1,002 to 4,911)
Controls 483** 211** 75** 2106** 285*
(119 to 1,274) (2174 to 78) (261 to 654) (2376 to 382) (2303 to 189)
p-value 0.221 0.014 0.027 0.014 0.021
IL-10 Patients 20000
(0 to 27) (219 to 5) (227 to 3) (221 to 52) (227 to 27)
Controls 55/24 25/21 34/6 24/12 28/23**
(1 to 187) (220 to 10) (23 to 186) (23t o7 1 ) ( 256 to 37)
p-value 0.314 0.712 0.097 0.201 0.518
IL-12 Patients 00022
(0 to 31) (219 to 7) (222 to 3) (230 to 7) (231 to 17)
C o n t r o l s 1021 2 1
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multiple cytokines has been suggested previously [23]. By assessing
both IP-10 response and IFN-c response, Ruhwald et al. noted an
increase in detection rate to 90% (i.e., detection by either cytokine)
from 83% and 81%, respectively, for IP-10 or IFN-c alone.
Individual cytokines have been found to be down-regulated in
some patients with tuberculosis, suggesting that assessment of
multiple cytokines may reduce the possibility of a negative
response with any single analyte [41].
The amount of cytokine in unstimulated plasma from patients
with CCTB was generally not significantly different from the
amount in unstimulated plasma from control subjects. However,
background levels of IP-10, MCP-1, and MIP-1b measured with
the custom MMIA were statistically higher for patients than for
controls. This observation has also been made for IP-10 and
MCP-3 previously [24,42]. The specificity and sensitivity of this
observation for Mtb infection should be further investigated. If
these cytokines are consistently elevated without antigen stimula-
tion in Mtb infected persons, as opposed to those with other
infections, they could serve as the basis for a more rapid test for
Mtb infection. If antigen stimulation is not required, detection of
elevated cytokine levels in the urine may be of diagnostic value
[43].
IP-10 has been targeted as a potential diagnostic marker for
tuberculosis in other studies [20–24,26,42,44–48]. In conjunction
with our results, these studies provide clear evidence that IP-10 is
produced in nanogram amounts when fresh blood samples from
most sensitized persons are stimulated with mycobacterial
antigens. Azzurri et al. noted an association between unstimulated
IP-10 plasma levels and disease activity, as well as response to
treatment [20]. In a pilot study, Syed Ahamed Kabeer et al. found
that tuberculosis treatment was associated with a significant
decrease in IP-10 response to certain peptides representing ESAT-
6 and CFP-10 [49]. Other promising indicators of Mtb infection
include antigen-induced MCP-2, MCP-3, and IL-1RA responses
[23,24,42,44].
The antigen or combination of antigens used to stimulate blood
can have a dramatic impact on the magnitude of the cytokine
response observed. Among sensitized persons, the number of
epitopes in an antigen and Major Histocompatibility Complex
(MHC) restrictions determines the number of T-lymphocyte
clones that will be stimulated by the antigen, and in turn, affects
the amount of IFN-c released upon stimulation [40,50]. For
example, among CCTB patients, IFN-c responses measured by
ELISA to ESAT-6+CFP-10 or ESAT-6+CFP-10+TB7.7 were
greater than the response to any of the individual antigens alone.
However, the IFN-c response to ESAT-6+CFP-10+TB7.7 was not
significantly greater than the response to ESAT-6+CFP-10. This
trend toward higher response to the combination antigens
continued for other cytokines measured with the in-house MMIA.
For this reason, and because ESAT-6+CFP-10+TB7.7 is used in
the QuantiFERONH-TB Gold In-Tube test, only responses to
ESAT-6+CFP-10+TB7.7 were measured with the custom com-
mercial MMIA.
Cytokine levels vary considerably from individual to individual,
so the range of values observed with the multiplexed assays was
rather large. Despite these large variations and the relatively small
sample sizes, significant differences between CCTB patients and
controls were observed, and measurements of IL-2, IL-6, IP-10,
and MIP-1b responses allowed complete separation of the two
groups. The dot plots and histograms (Figures 2 and 3) illustrate
the multiple sizeable cytokine responses and the pattern seen
among patients. For IP-10 and MIP-1b, the magnitude of the
responses to Mtb antigens was so large compared to background
cytokine levels that subtraction of the background had little effect
on the calculated responses. This has two implications. First, the
complexity and cost of testing may be reduced by screening only
Mtb-antigen stimulated plasma for characteristically high cytokine
concentrations. If increased concentrations of IP-10 or MIP-1b are
found in the Mtb-antigen stimulated plasma, a more sensitive and
complex assay could be performed that would take into account
the background cytokine concentrations. Second, significant
cytokine responses may be detectable with shorter incubation
times, thus allowing for more rapid assessments.
Differences are often seen in the magnitude of cytokine
concentrations measured with different ELISAs or different
multiplexed immunoassay systems [51]. These differences are
primarily due to varying antibody affinities for the assay targets, as
well as differences in the platforms employed. We used three
multiplexed immunoassay systems that assessed some of the same
cytokines with presumably different capture and detection
antibodies. In all three systems, differences in IL-2, IL-6, IL-8,
and IFN-c responses between CCTB patients and controls were
significant. In two systems, differences in MCP-1 and MIP-1b
responses were significant. TNF-a responses were significantly
greater among patients versus controls using the in-house MMIA
and commercial MMIA, but not when using the microarray.
However, TNF-a concentrations were generally low and highly
variable, which may explain why the differences in TNF-a
response were not significant for all three assays.
Limitations of this study stem from the examination of small
subsets of subjects with each of the different multiplexed
Cytokine Subject Group Nil ESAT-6 Response CFP-10 Response
ESAT-6+CFP-10
Response
ESAT-6+CFP-
10+TB7.7
Response
(0 to 743) (25 to 16) (0 to 54) (218 to 48) (245 to 164)
p-value 0.283 0.469 0.151 0.153 0.936
Median background cytokine concentrations (Nil, pg/mL) and cytokine responses (pg/mL) to phytohemagglutinin (Mitogen Response), early secreted antigenic target-6
(ESAT-6 Response), culture filtrate protein 10 (CFP-10 Response), TB7.7 (TB7.7 Response), and combinations of these M. tuberculosis (Mtb) antigens (ESAT-6+CFP-10
Response and ESAT-6+CFP-10+TB7.7 Response) are listed with ranges in parentheses. Cytokine concentrations were measured by a commercial quantitative immuno-
microaray (microarray) for patients with culture-confirmed tuberculosis (patients) and subjects at low risk for Mtb exposure (controls). Responses were calculated by
subtracting the background cytokine concentration in plasma from blood incubated with saline (Nil) from the cytokine concentration in plasma from blood incubated
with mitogen or Mtb antigens. Cytokine responses for some patients and controls were not determined due to poor performance of the respective standard curves.
N=5 or 6 for patients subjects and N=6 or 7 for controls unless indicated (*n=4, **n=5). P values were calculated by Mann-Whitney U Rank Sum test comparing
cytokine concentrations or responses for patients with controls. Significant differences (p,0.05) are indicated in bold type.
doi:10.1371/journal.pone.0026545.t006
Table 6. Cont.
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Cytokine Subject Group Nil ESAT-6 Response CFP-10 Response
ESAT-6+CFP-10
Response
ESAT-6+CFP-
10+TB7.7 Response
IL-13 Patients 06278
(0 to 40) (0 to 32) (0 to 21) (0 to 21) (25 to 17)
C o n t r o l s 1 2 0200
(0 to 484) (233 to 49) (0 to 172) (289 to 184) (2140 to 3)
p-value 0.115 0.192 0.664 0.174 0.076
GM-CSF Patients 3041 2 1 4
(0 to 112) (25t o4 4 ) ( 229 to 32) (250 to 107) (278 to 115)
C o n t r o l s 1 7 2060
(0 to 540) (23 to 108) (218 to 65) (2117 to 22) (2272 to 23)
p-value 0.390 0.469 0.717 0.431 0.197
GRO Patients 2,811 735 706 829 880
(183 to 3,875) (21,313 to 2,384) (21,083 to 4,907) (22,008 to 7,074) (22,547 to 37,398)
Controls 2,468 71 242 296 2150
(387 to 86,052) (2769 to 1,661) (2499 to 4,487) (214,640 to 2,782) (223,190 to 833)
p-value 0.475 0.668 0.668 0.391 0.200
MCP-1 Patients 20,392 72,572 102,845 76,846 72,438
(5,954 to 276,527) (26,792 to 273,723) (39,217 to 273,765) (56,043 to 273,741) (34,099 to 273,614)
Controls 10,289 641 254 297 3,900
(1,429 to 44,833) (22,416 to 22,637) (25,741 to 52,258) (27,145 to 30,559) (217,689 to 20,497)
p-value 0.253 0.003 0.004 0.004 0.004
MIP-1a Patients 19 284 269 123 2,107
(1 to 505) (17 to 5,688) (0 to 1,000) (18 to 2,690) (249 to 13,538)
Controls 315 24 221 1 6**
(6 to 5,950) (0 to 846) (210 to 639) (22,153 to 61) (24,872 to 74)
p-value 0.410 0.272 0.465 0.028 0.047
MIP-1b Patients 289 13,458 15,682 18,155 25,109
(154 to 15,734) (3,933 to 29,494) (3,702 to 29,263) (2,105 to 29,484) (4,745 to 37,410)
Controls 336 111 59 106 274
(33 to 453) (24 to 272) (266 to 426) (2324 to 590) (2361 to 418)
p-value 0.465 0.006 0.006 0.006 0.009
MMP-9 Patients 185,949 271 15,740 15,639 2148
(94,883 to 326,513) (28 to 98,216) (245 to 119,810) (235,972 to 121,997) (281,276 to 121,819)
Controls 219,901 9,230 52,022 40,621 210**
(94,886 to 379,856) (232,479 to 88,506) (0 to 93,451) (228,509 to 144,182) (235,664 to 126,870)
p-value 0.584 0.855 0.855 0.855 0.465
RANTES Patients 20,988 548 5,149 212 3,238
(8,034 to 42,202) (229,902 to 74,284) (25,196 to 74,287) (233,996 to 74,252) (239,618 to 74,266)
Controls 25,468 2 720 5,213 2,871
(8,033 to 43,474) (212,265 to 7,702) (221,765 to 28,541) (229,131 to 36,499) (233,264 to 20,574)
p-value 0.886 0.475 0.668 1.000 0.522
TNF-a Patients 2103 6 1 4 3
(0 to 207) (242 to 77) (253 to 29) (269 to 127) (2115 to 173)
Controls 15 0 16 6 21
(1 to 4,590) (2310 to 231) (2842 to 721) (21,191 to 361) (21,656 to 94)
p-value 0.223 0.871 0.806 0.570 0.100
VEGF Patients 306* 240* 264* 2203* 2139*
(0 to 400) (2179 to 25) (2191 to 248) (2277 to 35) (2216 to 0)
Controls 335 217 28 11 24**
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ESAT-6+CFP-10
Response
ESAT-6+CFP-
10+TB7.7 Response
(35 to 432) (2114 to 90) (244 to 162) (261 to 164) (287 to 180)
p-value 1.000 0.831 0.522 0.055 0.142
Median background cytokine concentrations (Nil, pg/mL) and cytokine responses (pg/mL) to phytohemagglutinin (Mitogen Response), early secreted antigenic target-6
(ESAT-6 Response), culture filtrate protein 10 (CFP-10 Response), TB7.7 (TB7.7 Response), and combinations of these M. tuberculosis (Mtb) antigens (ESAT-6+CFP-10
Response and ESAT-6+CFP-10+TB7.7 Response) are listed with ranges in parentheses. Cytokine concentrations were measured by a commercial quantitative immuno-
microaray (microarray) for patients with culture-confirmed tuberculosis (patients) and subjects at low risk for Mtb exposure (controls). Responses were calculated by
subtracting the background cytokine concentration in plasma from blood incubated with saline (Nil) from the cytokine concentration in plasma from blood incubated
with mitogen or Mtb antigens. Cytokine responses for some patients and controls were not determined due to poor performance of the respective standard curves.
N=5 or 6 for patients subjects and N=6 or 7 for controls unless indicated (*n=4, **n=5). P values were calculated by Mann-Whitney U Rank Sum test comparing
cytokine concentrations or responses for patients with controls. Significant differences (p,0.05) are indicated in bold type.
doi:10.1371/journal.pone.0026545.t007
Table 7. Cont.
Table 8. Comparisons of cytokine responses to different antigens measured by Microarray among patients with culture-confirmed
tuberculosis.
Cytokine ESAT-6 ESAT-6 ESAT-6 CFP-10 CFP-10 ESAT-6+CFP-10
vs. vs. vs. vs. vs. vs.
CFP-10 ESAT-6+CFP-10 ESAT-6+CFP-10+TB7.7 ESAT-6+CFP-10 ESAT-6+CFP-10+TB7.7 ESAT-6+CFP-10+TB7.7
IFN-g 682 682 682 763 763 1,270
vs. vs. vs. vs. vs. vs.
763 1,270 1,259 1,270 1,259 1,259
(0.463) (0.116) (0.345) (0.249) (0.345) (0.463)
IL-2 428 428 428 499 499 740
vs. vs. vs. vs. vs. vs.
499 740 746 740 746 746
(0.249) (0.046) (0.046) (0.116) (0.116) (0.249)
IL-6 250 250 250 28 28 182
vs. vs. vs. vs. vs. vs.
28 182 781 182 781 781
(0.046) (0.917) (0.173) (0.116) (0.028) (0.249)
IL-8 1,038 1,038 1,038 1,988 1,988 1,595
vs. vs. vs. vs. vs. vs.
1,988 1,595 3,076 1,595 3,076 3,076
(0.273) (0.068) (0.144) (0.715) (0.715) (0.715)
MCP-1 72,572 72,572 72,572 102,845 102,845 76,846
vs. vs. vs. vs. vs. vs.
102,845 76,846 72,438 76,846 72,438 72,438
(0.600) (0.686) (0.345) (0.043) (0.917) (0.893)
MIP-1a 284 284 284 269 269 123
vs. vs. vs. vs. vs. vs.
269 123 2,107 123 2.107 2,107
(0.686) (0.686) (0.138) (0.345) (0.138) (0.138)
MIP-1b 13,458 13,458 13,458 15,682 15,682 18,155
vs. vs. vs. vs. vs. vs.
15,682 18,155 25,109 18,155 25,109 25,109
(0.893) (0.893) (0.686) (0.893) (0.138) (0.686)
Median cytokine responses (from Tables 6 and 7) to early secreted antigenic target-6 (ESAT-6), culture filtrate protein 10 (CFP-10), and combinations of these M.
tuberculosis (Mtb) antigens (with or without TB7.7) for patients with culture-confirmed tuberculosis (patients) are listed with p values in parenthesis calculated by Mann-
Whitney U Rank Sum test. Significant differences (p,0.05) are indicated in bold type.
doi:10.1371/journal.pone.0026545.t008
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Cytokine Subject Group Nil Mitogen Response ESAT-6+CFP-10+TB7.7 Response
IFN-c Patients 165 2,002 913
(0 to 885) (502 to 3,791) (108 to 2,974)
Controls 79 1,930 38
(0 to 827) (766 to 3,459) (28 to 190)
p-value 0.184 0.908 ,0.001
IL-2 Patients 10 332 286
(0 to 35) (30 to 1,081) (37 to 1,553)
Controls 6 590 2
(0 to 63) (160 to 1,340) (27 to 11)
p-value 0.222 0.033 ,0.001
IL-6 Patients 34 6,941 438
(0 to 156) (222 to 25,260) (58 to 1,302)
Controls 11 5,146 11
(0 to 49) (608 to 9,632) (22 to 46)
p-value 0.202 0.817 ,0.001
IL-8 Patients 199 17,810 2,682
(40 to 819) (227 to 90,979) (135 to 21,942)
Controls 247 9,182 170
(41 to 635) (2,093 to 29,080) (222 to 735)
p-value 0.166 0.564 ,0.001
IL-12 Patients 0 4 0
(0 to 0) (0 to 19) (0 to 0)
Controls 2 4 0
(0 to 25) (0 to 18) (0 to 1)
p-value 0.317 0.829 0.317
IP-10 Patients 3,807 26,252 39,065
(143 to 25,641) (6,786 to 58,752) (2,530 to 158,425)
Controls 589 25,663 21
(149 to 1,275) (5,687 to 62,714) (2202 to 349)
p-value 0.033 0.954 ,0.001
MCP-1 Patients 2,879 20,372 13,729
(39 to 12,764) (4,842 to 44,202) (2221 to 39,519)
Controls 290 19,525 494
(28 to 1,319) (4,418 to 44,461) (272 to 1,899)
p-value 0.024 0.908 ,0.001
MIP-1b Patients 373 47,076 8,245
(60 to 1,389) (20,657 to 75,448) (773 to 24,204)
Controls 180 46,596 64
(59 to 415) (20,537 to 75,511) (0 to 198)
p-value 0.021 0.817 ,0.001
TNF-a Patients 65 3,268 303
(0 to 329) (250 to 6,715) (42 to 719)
Controls 9 1,470 14
(0 to 105) (491 to 3,910) (0 to 94)
p-value 0.074 0.184 ,0.001
Median background cytokine concentrations (Nil, pg/mL) and cytokine responses (pg/mL) to phytohemagglutinin (Mitogen Response) and to a combination of early
secreted antigenic target-6, culture filtrate protein 10, and TB7.7 (ESAT-6+CFP-10+TB7.7 Response) are listed with ranges in parentheses. Cytokine concentrations were
measured with a custom commercial multiplexed microsphere-based immunoassay (commercial MMIA) for patients with culture-confirmed tuberculosis (patients) and
subjects at low risk for M. tuberculosis (Mtb) infection (controls). For values that were designated ‘‘out of range’’ by Bio-Plex Manager software, low values are reported as
0 and high values are reported as the observed value of the highest standard concentration multiplied by the dilution factor. Responses were calculated by subtracting
the background cytokine concentration in plasma from blood incubated with saline (Nil) from the cytokine concentration in plasma from blood incubated with mitogen
or Mtb antigen. N=12 for patients and N=12 for controls. P values were calculated by Mann-Whitney U Rank Sum test comparing cytokine concentrations or responses
for patients versus controls. Significant differences (p,0.05) are indicated in bold type.
doi:10.1371/journal.pone.0026545.t009
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PLoS ONE | www.plosone.org 14 November 2011 | Volume 6 | Issue 11 | e26545Figure 2. (A–H): Responses of eight cytokines to specific M. tuberculosis antigens. Cytokine responses to a peptide cocktail representing
early secreted antigenic target-6, culture filtrate protein 10, and TB7.7 (ESAT-6+CFP-10+TB7.7) are depicted for the 12 patients with culture-confirmed
tuberculosis (patients) and 12 subjects at low risk for Mtb infection (controls) represented in Table 9. Cytokine concentrations were measured with a
custom commercial multiplexed microsphere-based immunoassay (commercial MMIA). Note the split y-axis. The dotted line and value in parentheses
represents the mean cytokine response for controls plus three standard deviations, which was used as a cut point to separate positive and negative
responses. Panels A through H depict IFN-c, IL-2, IL-6, IL-8, TNF-a, IP-10, MCP-1, and MIP-1b responses.
doi:10.1371/journal.pone.0026545.g002
Figure 3. (A–B): Patterns of cytokine responses. Patterns of cytokine response to a peptide cocktail representing early secreted antigenic
target-6, culture filtrate protein 10, and TB7.7 (ESAT-6+CFP-10+TB7.7) are depicted for 12 patients with culture-confirmed tuberculosis (patients) in
Panel A, and for 12 subjects at low risk for Mtb infection (controls) in Panel B that were summarized in Table 9. Cytokine concentrations were
measured with a custom commercial multiplexed microsphere-based immunoassay (commercial MMIA). Responses were calculated by subtracting
the background cytokine concentration in plasma from blood incubated with saline (Nil) from the cytokine concentration in plasma from blood
incubated with Mtb antigens.
doi:10.1371/journal.pone.0026545.g003
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significant differences in cytokine responses were demonstrated
between CCTB patients and controls. While differences in
demographic and clinical characteristics for the patient and
control populations were observed (listed in Table 1), it is unlikely
that these explain the differences in cytokine responses seen.
Subtracting the background cytokine concentration (in the Nil
plasma) from the concentration in the antigen stimulated plasma
adjusts for demographic and clinical factors that may contribute to
nonspecific release of cytokines. The observed differences in
unstimulated concentrations for some cytokines (including IFN-c)
is likely due to elevated background levels of cytokine associated
with acute or chronic illness, including tuberculosis. Another
limitation is the lack of adequate diagnostic standards to confirm
all forms of Mtb infection, including the most common, which is
latent infection. We addressed this limitation by comparing
responses among patients with confirmed Mtb infection (i.e.,
among patients with tuberculosis confirmed by recovery of Mtb by
culture) and control subjects at low-risk of Mtb exposure who were
presumed to be uninfected. Clearly, immunologic differences exist
between latent Mtb infection and infection manifesting as active
disease, but specific immunologic differences have been difficult to
demonstrate [26,52]. Larger epidemiologically based studies will
be required to identify and confirm these differences. Multiplexed
assays, which can be readily automated for high-throughput, can
facilitate these larger studies.
MMIAs, which are also referred to as suspension arrays, are
gaining wide acceptance as tools for research and diagnostic assays
[53,54]. These assays are performed in 2 to 4 hours, similar to the
time required to perform ELISAs. However, in addition to
measuring more than one analyte per test, MMIAs require smaller
sample volumes (4 mL in this study), less amounts of reagent and
operator time, and cost less than multiple ELISAs. These three
dimensional assays have a detection range 1–2 logs broader than
ELISAs, so fewer sample dilutions are necessary. Already a
simpler, less expensive instrument is available that is not
dependent on the fluidics system of a flow cytometer (MAGPIXH,
Luminex Corporation). This and similar systems are more
compact and portable and show potential for use in developing
regions of the world where both reduction in assay cost and time
delay between diagnosis and treatment are important. As
multiplexed assays that show potential for detection of Mtb
infection are optimized, they can be incorporated onto other
platforms that are fully automated or designed for point-of-care
diagnostics.
In conclusion, multiple cytokines are released when whole blood
samples from patients with CCTB are stimulated with specific Mtb
antigens. Compared with measurement of IFN-c alone, multi-
plexed assays can improve diagnostic sensitivity for Mtb infection
by assessing multiple cytokine responses simultaneously, using
smaller sample volumes and reducing the cost of testing compared
to ELISAs and other methods. The use of combinations of specific
Mtb antigens may also increase diagnostic sensitivity by increasing
the magnitude of cytokine responses as compared to individual
antigens. Larger studies are needed to confirm the clinical utility of
multiplexed assays that examine the cytokines identified in this
study as potential diagnostic markers of Mtb infection and to
examine the possibility of differentiating infection with disease
from latent infection.
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